Overview

Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCOREⅡ）

Status:
Not yet recruiting

Trial end date:
2029-05-01

Target enrollment:

Participant gender:

Summary

This is a Phase 3, prospective, randomized, open-label, multi-center international study that assesses the efficacy and safety of neoadjuvant therapy with different cycles of sintilimab combined with chemotherapy for Resectable Squamous Cell NSCLC. This trial will also explore the biomarkers of neoadjuvant immunochemotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

Second Affiliated Hospital, School of Medicine, Zhejiang University

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel